ClinicalTrials.gg
CompletedNCT00379769RECORDUpdated Mar 23, 2017Results posted

RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes

A Phase 3 interventional study of Rosiglitazone and Sulfonylurea in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Completed at 447 sites in 25 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-03-23.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,447
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Rosiglitazone · Diabetes Mellitus, Type 2.

Enrollment
Largest of 51
4,447 · median 149
Started
2001
with 2 others
Phase 3
21 of 52
none open now
Registered
30th of 52
by date
Lead sponsor
22 of 52
GlaxoSmithKline

Among the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2, this one has the largest enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2001, is one of 21 in phase 3, and was the 30th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About rosiglitazone

Rosiglitazone: first FDA approval 1999 (AVANDIA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 52 studies testing rosiglitazone in Diabetes Mellitus, Type 2 as a file.
02

Study summary

This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background glucose lowering therapy. Patients inadequately controlled on background metformin will be randomised to receive, in addition to metformin, either rosiglitazone or a sulfonylurea(glibenclamide, gliclazide or glimepiride) in a ratio of 1:1. Patients inadequately controlled on background SU will be randomised to receive, in addition to SU, either rosiglitazone or metformin in a ratio of 1:1. Equal numbers of patients receiving background metformin and SU at entry will be entered into the study.

Read the detailed description

A RECORD follow-up study is being performed to monitor the incidence of cancer and bone fractures in RECORD patients for a period of 4 years after the end of the main RECORD study (2008 - 2012).

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • diabetes
  • CV outcomes
  • rosiglitazone
  • Type II diabetes
  • sulfonylurea
  • RECORD
  • metformin
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type II diabetes mellitus as defined by 1999 World Health Organisation criteria.
  • (HbA1c) >7.0 % to = 9.0 % at visit 1.
  • Use of an oral glucose lowering agent for a minimum of 6 months prior to screening and unchanged for 2 months prior to screening.
  • >25.0 kg/m2.

Exclusion criteria

Exclusion Criteria:

  • Patients receiving any other glucose lowering therapy which is not metformin or a sulfonylurea.
  • Patients with systolic blood pressure >180 mmHg or diastolic blood pressure >105 mmHg.
  • Patients who have required the use of insulin for glycaemic control at any time in the past.
  • Hospitalisation for any major cardiovascular event in the last 3 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4,447 participants (actual)

Study arms

  • Experimental
    rosiglitazone in addition to background metformin

    Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.

    Drug: Rosiglitazone · Drug: Metformin

  • Experimental
    rosiglitazone in addition to background sulfonylurea

    Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.

    Drug: Rosiglitazone · Drug: Sulfonylurea

  • Active comparator
    Sulfonylurea in addition to background metformin

    Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.

    Drug: Sulfonylurea · Drug: Metformin

  • Active comparator
    Metformin in addition to background sulfonylurea

    Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.

    Drug: Sulfonylurea · Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events

    The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded.

    Time frame: Baseline through End of Study (up to 7.5 years)

  2. Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause

    All deaths identified during the original record study and discovered after the re-adjudication efforts began were included.

    Time frame: Baseline through End of Study (up to 7.5 years)

  3. Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions

    IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin.

    Time frame: Baseline through End of Study (up to 7.5 years)

  4. Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions

    Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.

    Time frame: Baseline through End of Study (up to 7.5 years)

  5. Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions

    The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as "unknown deaths," but were counted as CV deaths for the analysis of this endpoint.

    Time frame: Baseline through End of Study (up to 7.5 years)

  6. Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions

    The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths.

    Time frame: Baseline through End of Study (up to 7.5 years)

  7. Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions

    The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme \>= 2x the ULN or CK \> 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI.

    Time frame: Baseline through End of Study (up to 7.5 years)

  8. Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions

    The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.

    Time frame: Baseline through End of Study (up to 7.5 years)

  9. Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions

    Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke.

    Time frame: Baseline through End of Study (up to 7.5 years)

  10. Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions

    The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.

    Time frame: Baseline through End of Study (up to 7.5 years)

Secondary outcomes

  1. Number of Participants With Cardiovascular Events and All-cause Deaths

    Composites of participants with first cardiovascular (CV) hospitalisations and CV death or all-cause death and individual first events of acute myocardial infarction (MI) , stroke, congestive heart failure (CHF), CV death, and all-cause death.

    Time frame: Baseline through End of Study (up to 7.5 years)

  2. Total Number of Cardiovascular Hospitalisations and Cardiovascular Deaths

    The total number of events for individual components of cardiovascular (CV) hospitalisations and cardiovascular deaths were recorded. MI, myocardial infarction.

    Time frame: Baseline through End of Study (up to 7.5 years)

  3. Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum

    Participants with first cardiovascular death (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) were recorded by study stratum.

    Time frame: Baseline through End of Study (up to 7.5 years)

  4. Number of Participants With CV/Microvascular Events

    The number of participants with first cardiovascular or microvascular events (renal, foot, eye) were recorded.

    Time frame: Baseline through End of Study (up to 7.5 years)

  5. Number of Participants With Glycaemic Failure Events

    Failure of glycaemic control was defined as two consecutive HbA1c values of ≥8.5 percent, or HbA1c ≥8.5percent at a single visit, after which the subject was either moved to the post-randomised treatment phase or triple therapy was started.

    Time frame: Baseline through to end of randomised dual therapy

  6. Number of Participants With Addition of Third Oral Agent/Switch to Insulin

    The number of participants with addition of a third oral agent or switch to insulin from randomised dual combination treatment were recorded.

    Time frame: Baseline through End of Study (up to 7.5 years)

  7. The Number of Participants Starting Insulin at Any Time During the Study

    The number of participants starting insulin at any time during the study was recorded.

    Time frame: Baseline through End of Study (up to 7.5 years)

  8. Model Adjusted Change From Baseline in HbA1c at Month 60

    Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in HbA1c was calculated as the value at Month 60 minus the Baseline value.

    Time frame: Baseline and Month 60 of randomised dual therapy treatment period

  9. Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60

    Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in fasting plasma glucose was calculated as the value at Month 60 minus the Baseline value.

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment period

  10. Model Adjusted Mean Change From Baseline in Insulin and Pro-insulin at Month 60

    Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in insulin and pro-insulin was calculated as the value at Month 60 minus the Baseline value.

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment period

  11. Number of HbA1c and Fasting Plasma Glucose (FPG) Responders at Month 60

    Number of responders, i.e., participants meeting glycaemic targets (HbA1c less than or equal to 7 percent, FPG less than or equal to 7 mmol/L)

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment period

  12. Model Adjusted Ratio to Baseline (Expressed as a Percentage) Homeostasis Model Assessment (HOMA) Beta Cell Function and Insulin Sensitivity at Month 60

    The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in HOMA beta-cell function and insulin sensitivity was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  13. Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC), Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Triglycerides, and Free Fatty Acids (FFAs) at Month 60

    The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC, LDL cholesterol, HDL cholesterol, triglycerides, and FFAs was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  14. Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC):High-density Lipoprotein (HDL) Cholesterol and Low-density Lipoprotein (LDL) Cholesterol:HDL Cholesterol Ratios at Month 60

    The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC:HDL cholesterol and LDL cholesterol:HDL cholesterol was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment period

  15. Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60

    The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in Apo-B was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment period

  16. Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60

    The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in urinary albumin creatinine ratio was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  17. Model Adjusted Change From Baseline in Body Weight at Month 60

    Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in body weight was calculated as the value at Month 60 minus the Baseline value.

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  18. Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60

    Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in alanine aminotransferase was calculated as the value at Month 60 minus the Baseline value.

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  19. Model Adjusted Change From Baseline in Waist Circumference at Month 60

    Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in waist circumference was calculated as the value at Month 60 minus the Baseline value.

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  20. Model Adjusted Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 60

    Model adjusted (adjusted for any imbalances in the baseline values between within treatment groups) change from baseline in SBP and DBP was calculated as the value at Month 60 minus the Baseline value.

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  21. Model Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60

    The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in C-Reactive Protein was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  22. Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 60

    The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in fibrinogen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  23. Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60

    The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in plasminogen activator inhibitor-1 (PAI-1) antigen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

    Time frame: Baseline to Month 60 of the randomised dual therapy treatment phase

  24. Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Main Study + Observational Follow-up Combined

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  25. Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Observational Follow-up

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

    Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)

  26. Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Main Study + Observational Follow-up Combined

    The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  27. Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Observational Follow-up

    The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

    Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)

  28. Number of Participants Who Died Due to the Indicated Cancer-related Event: Main Study + Observational Follow-up Combined

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  29. Number of Participants Who Died Due to the Indicated Cancer-related Event: Observational Follow-up

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

    Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)

  30. Number of Participants With a Bone Fracture Event - Overall and by Gender: Main Study and Observational Follow-up Combined

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  31. Number of Participants With a Bone Fracture Event - Overall and by Gender: Observational Follow-up

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

    Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)

  32. Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Main Study + Observational Follow-up Combined

    The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  33. Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Observational Follow-up

    The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

    Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)

  34. Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  35. Number of Participants With the Indicated Bone Fracture by Fracture Site: Main Study + Observational Follow-up Combined

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  36. Number of Participants With the Indicated Bone Fracture by Fracture Site: Observational Follow-up

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

    Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)

  37. Number of Participants With Potentially High Morbidity Fractures: Main Study + Observational Follow-up Combined

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  38. Number of Participants With Potentially High Morbidity Fracture Events and Non-high Morbidity Fracture Events, in Participants With Prior Hand/Upper Arm/Foot Fractures (H/UA/FF): Main Study + Observational Follow-up Combined

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  39. Number of Participants With Bone Fracture Events of the Indicated Cause: Main Study + Observational Follow-up Combined

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  40. Number of Participants With Bone Fracture Events of the Indicated Cause: Observational Follow-up

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."

    Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)

  41. Number of Bone Fracture Events With the Indicated Outcome: Main Study + Observational Follow-up Combined

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."

    Time frame: From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)

  42. Number of Bone Fracture Events With the Indicated Outcome: Observational Follow-up

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."

    Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)

  43. Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up

    The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

    Time frame: From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)

07

Results

Posted Nov 13, 2009

Participant flow

The RECORD study ran from April 2001 through December 2008. Results are presented in the non-re-adjudicated outcome measures (OMs). An independent patient-level re-adjudication of mortality, non-fatal myocardial infarction, and non-fatal stroke began on January 2011 and ran through March 2012. The results are presented in the re-adjudicated OMs.

Main Study
Participant flow — Main Study
MilestoneRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SUCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Started111711051103112200
Completed93990689689200
Not completed17819920723000
Withdrew: Death5767547200
Withdrew: Adverse event58101100
Withdrew: Lost to follow-up2929252600
Withdrew: Withdrawal by subject4656727000
Withdrew: Moved to survival status follow-up only2725323600
Withdrew: Participant moved323300
Withdrew: Poor compliance322100
Withdrew: Prohibited glucose lowering medication030100
Withdrew: Site closed444800
Withdrew: Entry criteria violation001100
Withdrew: Participant did not take study drug001000
Withdrew: Physician decision221100
Withdrew: Participant completed study at visit 27100000
Withdrew: Personal reasons100000
Withdrew: Risk of heart failure010000
Withdrew: Investigator refused to log temperature001000
Withdrew: Reason unspecified001000
Observational Follow-up
Participant flow — Observational Follow-up
MilestoneRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SUCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Started000012801250
Completed000011311102
Not completed0000149148
Withdrew: Death00007870
Withdrew: Adverse event000010
Withdrew: Lost to follow-up00002527
Withdrew: Withdrawal by subject00001212
Withdrew: Entered into another clinical trial00001822
Withdrew: Physician decision000088
Withdrew: Site closed early000067
Withdrew: Participant moved000001
Withdrew: Unknown; reason not provided000011

Outcome measures

PrimaryNumber of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events

The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events
participantsCombined RSGCombined MET/SU
Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events321323
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 0.99 · 95% CI 0.85 to 1.16
SecondaryNumber of Participants With Cardiovascular Events and All-cause Deaths

Composites of participants with first cardiovascular (CV) hospitalisations and CV death or all-cause death and individual first events of acute myocardial infarction (MI) , stroke, congestive heart failure (CHF), CV death, and all-cause death.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Number of Participants With Cardiovascular Events and All-cause Deaths
participantsCombined RSGCombined MET/SU
CV death, acute MI, stroke154165
CV death, acute MI, stroke, unstable angina171184
CV death, acute MI, stroke, unstable angina, CHF204206
All-cause death,acuteMI,stroke,unstable angina,CHF251268
Acute MI (fatal or non-fatal)6456
Stroke (fatal or non-fatal)4663
CHF (fatal or non-fatal)6129
Death from CV causes6071
Death (all cause) during CV follow-up111139
Death (all-cause) including survival status136157
SecondaryTotal Number of Cardiovascular Hospitalisations and Cardiovascular Deaths

The total number of events for individual components of cardiovascular (CV) hospitalisations and cardiovascular deaths were recorded. MI, myocardial infarction.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · Number of events
Total Number of Cardiovascular Hospitalisations and Cardiovascular Deaths
Number of eventsCombined RSGCombined MET/SU
CV deaths6071
Death due to acute MI710
Death due to heart failure102
Sudden death812
Death due to acute vascular events110
Other CV mortality64
Death of presumed CV cause2833
Cardiovascular hospitalisation483490
Hospitalisation for acute MI6657
Hospitalisation for unstable angina2828
Hospitalisation for congestive heart failure6936
Hospitalisation for stroke5167
Hospitalisation for transient ischaemic attack1010
Hospitalisation for invasive CV procedure99116
Hospitalisation for amputation of extremities623
Other CV hospitalisations154153
SecondaryNumber of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum

Participants with first cardiovascular death (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) were recorded by study stratum.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · partcipants
Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum
partcipantsRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum158154163169
SecondaryNumber of Participants With CV/Microvascular Events

The number of participants with first cardiovascular or microvascular events (renal, foot, eye) were recorded.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Number of Participants With CV/Microvascular Events
participantsCombined RSGCombined MET/SU
Participants with a CV/Microvascular event363385
Participants with any microvascular event5978
Participants with any eye event4252
Participants with any foot event1928
Participants with any renal event00
SecondaryNumber of Participants With Glycaemic Failure Events

Failure of glycaemic control was defined as two consecutive HbA1c values of ≥8.5 percent, or HbA1c ≥8.5percent at a single visit, after which the subject was either moved to the post-randomised treatment phase or triple therapy was started.

Time frame:
Baseline through to end of randomised dual therapy
Reported as:
Number · participants
Number of Participants With Glycaemic Failure Events
participantsRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Number of Participants With Glycaemic Failure Events281451365424
SecondaryNumber of Participants With Addition of Third Oral Agent/Switch to Insulin

The number of participants with addition of a third oral agent or switch to insulin from randomised dual combination treatment were recorded.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Number of Participants With Addition of Third Oral Agent/Switch to Insulin
participantsRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Participants with an event295183344171
First Event - Triple Therapy25772966
First Event - Insulin3817649165
SecondaryThe Number of Participants Starting Insulin at Any Time During the Study

The number of participants starting insulin at any time during the study was recorded.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
The Number of Participants Starting Insulin at Any Time During the Study
participantsRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
The Number of Participants Starting Insulin at Any Time During the Study126276168259
SecondaryModel Adjusted Change From Baseline in HbA1c at Month 60

Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in HbA1c was calculated as the value at Month 60 minus the Baseline value.

Time frame:
Baseline and Month 60 of randomised dual therapy treatment period
Reported as:
Mean · Percent
Model Adjusted Change From Baseline in HbA1c at Month 60
PercentRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Change From Baseline in HbA1c at Month 60-0.14 ± 0.0350.17 ± 0.042-0.24 ± 0.039-0.10 ± 0.039
SecondaryModel Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60

Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in fasting plasma glucose was calculated as the value at Month 60 minus the Baseline value.

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment period
Reported as:
Mean · mmol/L (millimoles/Liter)
Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60
mmol/L (millimoles/Liter)RSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60-1.38 ± 0.073-0.29 ± 0.090-2.00 ± 0.085-0.94 ± 0.094
SecondaryModel Adjusted Mean Change From Baseline in Insulin and Pro-insulin at Month 60

Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in insulin and pro-insulin was calculated as the value at Month 60 minus the Baseline value.

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment period
Reported as:
Mean · picamoles/liter (pmol/L)
Model Adjusted Mean Change From Baseline in Insulin and Pro-insulin at Month 60
picamoles/liter (pmol/L)RSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Insulin, Adjusted Change from Baseline-18.6 ± 1.013.7 ± 1.77-16.9 ± 1.65-12.1 ± 1.91
Pro-insulin, Adjusted Change from Baseline-2.4 ± 0.264.2 ± 0.43-3.2 ± 0.48-3.0 ± 0.37
SecondaryNumber of HbA1c and Fasting Plasma Glucose (FPG) Responders at Month 60

Number of responders, i.e., participants meeting glycaemic targets (HbA1c less than or equal to 7 percent, FPG less than or equal to 7 mmol/L)

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment period
Reported as:
Number · participants
Number of HbA1c and Fasting Plasma Glucose (FPG) Responders at Month 60
participantsRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
HbA1c Responders265208235180
FPG Responders300180257154
SecondaryModel Adjusted Ratio to Baseline (Expressed as a Percentage) Homeostasis Model Assessment (HOMA) Beta Cell Function and Insulin Sensitivity at Month 60

The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in HOMA beta-cell function and insulin sensitivity was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Geometric mean · percent change
Model Adjusted Ratio to Baseline (Expressed as a Percentage) Homeostasis Model Assessment (HOMA) Beta Cell Function and Insulin Sensitivity at Month 60
percent changeRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Beta cell function20.54 (16.52 to 24.70)19.28 (14.66 to 24.09)32.35 (26.55 to 38.41)12.43 (7.42 to 17.67)
Insulin sensitivity42.57 (37.57 to 47.76)-3.45 (-7.21 to 0.47)42.07 (36.39 to 47.98)23.90 (19.36 to 28.61)
SecondaryModel Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC), Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Triglycerides, and Free Fatty Acids (FFAs) at Month 60

The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC, LDL cholesterol, HDL cholesterol, triglycerides, and FFAs was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Geometric mean · percent change
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC), Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Triglycerides, and Free Fatty Acids (FFAs) at Month 60
percent changeRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Total cholesterol-5.49 (-6.99 to -3.96)-9.09 (-10.33 to -7.84)-2.91 (-4.62 to -1.17)-9.68 (-11.03 to -8.31)
HDL-cholesterol9.95 (8.44 to 11.49)2.57 (1.46 to 3.68)7.73 (6.18 to 9.30)6.14 (4.88 to 7.42)
LDL-cholesterol-12.70 (-15.03 to -10.30)-17.68 (-19.70 to -15.61)-8.99 (-11.42 to -6.49)-17.80 (-19.93 to -15.61)
Triglycerides-7.97 (-10.72 to -5.15)-1.95 (-4.73 to 0.91)-2.68 (-5.69 to 0.43)-2.50 (-5.21 to 0.28)
Free fatty acids-16.46 (-19.13 to -13.71)2.79 (-0.23 to 5.91)-11.58 (-14.65 to -8.41)4.47 (1.23 to 7.81)
SecondaryModel Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC):High-density Lipoprotein (HDL) Cholesterol and Low-density Lipoprotein (LDL) Cholesterol:HDL Cholesterol Ratios at Month 60

The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in TC:HDL cholesterol and LDL cholesterol:HDL cholesterol was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment period
Reported as:
Geometric mean · percent change
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC):High-density Lipoprotein (HDL) Cholesterol and Low-density Lipoprotein (LDL) Cholesterol:HDL Cholesterol Ratios at Month 60
percent changeRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Total Cholesterol: HDL Cholesterol Ratio-14.20 (-15.98 to -12.39)-11.33 (-12.82 to -9.81)-9.93 (-11.83 to -7.98)-15.01 (-16.44 to -13.55)
LDL Cholesterol: HDL-Cholesterol Ratio-20.89 (-23.24 to -18.46)-20.04 (-22.16 to -17.87)-15.85 (-18.26 to -13.37)-22.53 (-24.63 to -20.37)
SecondaryModel Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60

The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in Apo-B was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment period
Reported as:
Geometric mean · percent change
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60
percent changeRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60-13.77 (-15.45 to -12.05)-11.63 (-13.10 to -10.14)-9.68 (-11.55 to -7.77)-12.09 (-13.67 to -10.47)
SecondaryModel Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60

The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in urinary albumin creatinine ratio was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Geometric mean · percent change
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60
percent changeRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 608.31 (-0.70 to 18.14)15.17 (6.73 to 24.28)-3.43 (-11.91 to 5.87)11.91 (3.10 to 21.46)
SecondaryModel Adjusted Change From Baseline in Body Weight at Month 60

Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in body weight was calculated as the value at Month 60 minus the Baseline value.

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Mean · kilograms
Model Adjusted Change From Baseline in Body Weight at Month 60
kilogramsRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Change From Baseline in Body Weight at Month 603.93 ± 0.263-0.54 ± 0.1924.72 ± 0.235-2.16 ± 0.179
SecondaryModel Adjusted Change From Baseline in Alanine Aminotransferase at Month 60

Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in alanine aminotransferase was calculated as the value at Month 60 minus the Baseline value.

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Mean · U/L (Units/Liter)
Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60
U/L (Units/Liter)RSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60-37.43 (-39.22 to -35.59)-21.73 (-23.90 to -19.50)-30.17 (-31.98 to -28.31)-24.00 (-26.21 to -21.73)
SecondaryModel Adjusted Change From Baseline in Waist Circumference at Month 60

Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in waist circumference was calculated as the value at Month 60 minus the Baseline value.

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Mean · cm (centimeters)
Model Adjusted Change From Baseline in Waist Circumference at Month 60
cm (centimeters)RSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Change From Baseline in Waist Circumference at Month 602.70 ± 0.2660.65 ± 0.2143.00 ± 0.263-0.60 ± 0.215
SecondaryModel Adjusted Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 60

Model adjusted (adjusted for any imbalances in the baseline values between within treatment groups) change from baseline in SBP and DBP was calculated as the value at Month 60 minus the Baseline value.

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Mean · mmHg (millimeters of mercury)
Model Adjusted Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 60
mmHg (millimeters of mercury)RSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
SBP-1.9 ± 0.54-2.2 ± 0.52-2.3 ± 0.52-0.6 ± 0.53
DBP-3.6 ± 0.34-3.4 ± 0.29-3.6 ± 0.31-2.3 ± 0.31
SecondaryModel Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60

The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in C-Reactive Protein was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Geometric mean · percent change
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60
percent changeRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60-57.40 (-60.41 to -54.15)-28.92 (-33.71 to -23.79)-56.50 (-61.56 to -55.21)-36.29 (-41.03 to -31.17)
SecondaryModel Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 60

The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in fibrinogen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Geometric mean · percent change
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 60
percent changeRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 602.12 (0.54 to 3.72)5.74 (4.22 to 7.28)-0.23 (-1.79 to 1.35)3.14 (1.38 to 4.93)
SecondaryModel Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60

The model adjusted (adjusted for any imbalances in the baseline \[BL\] values between within stratum treatment groups) ratio to BL in plasminogen activator inhibitor-1 (PAI-1) antigen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100\*\[GM\^-1\]).

Time frame:
Baseline to Month 60 of the randomised dual therapy treatment phase
Reported as:
Geometric mean · percent change
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60
percent changeRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SU
Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60-9.85 (-14.42 to -5.02)15.01 (9.77 to 20.50)-7.79 (-12.61 to -2.71)-0.64 (-5.82 to 4.83)
PrimaryIndependent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause

All deaths identified during the original record study and discovered after the re-adjudication efforts began were included.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause
participantsCombined RSGCombined MET/SU
Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause139160
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 0.86 · 95% CI 0.68 to 1.08
PrimaryIndependent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions

IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions
participantsCombined RSGCombined MET/SU
Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions181188
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 0.95 · 95% CI 0.78 to 1.17
PrimaryIndependent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions

Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions
participantsCombined RSGCombined MET/SU
Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions186191
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 0.97 · 95% CI 0.79 to 1.18
PrimaryIndependent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions

The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as "unknown deaths," but were counted as CV deaths for the analysis of this endpoint.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions
participantsCombined RSGCombined MET/SU
Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions8896
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 0.90 · 95% CI 0.68 to 1.21
PrimaryIndependent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions

The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions
participantsCombined RSGCombined MET/SU
Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions8896
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 0.90 · 95% CI 0.68 to 1.21
PrimaryIndependent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions

The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme \>= 2x the ULN or CK \> 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions
participantsCombined RSGCombined MET/SU
Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions6860
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 1.13 · 95% CI 0.80 to 1.59
PrimaryIndependent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions

The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions
participantsCombined RSGCombined MET/SU
Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions7262
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 1.15 · 95% CI 0.82 to 1.62
PrimaryIndependent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions

Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions
participantsCombined RSGCombined MET/SU
Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions5063
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 0.79 · 95% CI 0.54 to 1.14
PrimaryIndependent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions

The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.

Time frame:
Baseline through End of Study (up to 7.5 years)
Reported as:
Number · participants
Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions
participantsCombined RSGCombined MET/SU
Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions5364
Statistical analysis
  • Combined RSG vs Combined MET/SU · Hazard ratio (hr): 0.82 · 95% CI 0.57 to 1.18
SecondaryNumber of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Main Study + Observational Follow-up Combined

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Main Study + Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
All neoplasms/cancer (N/C) (benign/malignant)196215
Malignant (Mal.) N/C179195
Mal. N/C; excluding non-melanomatous skin cancers164186
SecondaryNumber of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Observational Follow-up

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

Time frame:
From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Reported as:
Number · participants
Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Observational Follow-up
participantsCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
All neoplasms/cancer (N/C) (benign/malignant)6051
Malignant (Mal.) N/C5951
Mal. N/C; excluding non-melanomatous skin cancers5546
SecondaryNumber of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Main Study + Observational Follow-up Combined

The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Main Study + Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Any genitourinary5757
Prostate2222
Renal129
Uterine1116
Bladder85
Vaginal/vulvar11
Ovarian54
Any gastrointestinal4862
Colon/rectal cancer2230
Colon1421
Gastric135
Pancreatic516
Liver45
Gall bladder/biliary45
Gastrointestinal; not specified01
Any hematologic126
Lung1915
Skin (non-melanomatous)1913
Skin (melanomatous)64
Metastases1218
Breast1223
Head and neck47
Neurologic33
Endocrine36
Not specified01
Other03
SecondaryNumber of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Observational Follow-up

The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

Time frame:
From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Reported as:
Number · participants
Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Observational Follow-up
participantsCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Any genitourinary188
Prostate71
Renal52
Uterine44
Bladder20
Vaginal/vulvar01
Ovarian00
Any gastrointestinal1719
Colon/rectal cancer511
Colon27
Gastric51
Pancreatic43
Liver22
Gall bladder/biliary11
Gastrointestinal; not specified01
Any hematologic61
Lung66
Skin (non-melanomatous)65
Skin (melanomatous)32
Metastases36
Breast27
Head and neck21
Neurologic11
Endocrine01
Not specified00
Other00
SecondaryNumber of Participants Who Died Due to the Indicated Cancer-related Event: Main Study + Observational Follow-up Combined

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants Who Died Due to the Indicated Cancer-related Event: Main Study + Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Any cancer-related death5972
Any gastrointestinal event2534
Pancreatic412
Colon/rectal611
Gastric73
Liver44
Gall bladder/biliary43
Gastrointestinal event; not specified01
Any genitourinary event615
Renal23
Uterine15
Prostate12
Bladder13
Ovarian12
Lung1311
Any hematologic event40
Skin (melanoma)30
Skin (non-melanomatous)10
Metastases24
Breast23
Head and neck12
Any neurologic event22
Endocrine10
Not specified01
SecondaryNumber of Participants Who Died Due to the Indicated Cancer-related Event: Observational Follow-up

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

Time frame:
From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Reported as:
Number · participants
Number of Participants Who Died Due to the Indicated Cancer-related Event: Observational Follow-up
participantsCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Any cancer-related death2524
Any gastrointestinal event1014
Pancreatic33
Colon/rectal26
Gastric21
Liver22
Gall bladder/biliary11
Gastrointestinal event; not specified01
Any genitourinary event20
Renal10
Uterine10
Prostate00
Bladder00
Ovarian00
Lung45
Any hematologic event40
Skin (melanoma)10
Skin (non-melanomatous)10
Metastases11
Breast13
Head and neck10
Any neurologic event11
Endocrine00
Not specified00
SecondaryNumber of Participants With a Bone Fracture Event - Overall and by Gender: Main Study and Observational Follow-up Combined

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants With a Bone Fracture Event - Overall and by Gender: Main Study and Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Overall, n=2220, 2227238151
Male, n=1142, 11528260
Female, n=1078, 107515691
SecondaryNumber of Participants With a Bone Fracture Event - Overall and by Gender: Observational Follow-up

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

Time frame:
From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Reported as:
Number · participants
Number of Participants With a Bone Fracture Event - Overall and by Gender: Observational Follow-up
participantsCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Overall, n=1280, 12506437
Male, n=665, 6352511
Female, n=615, 6153926
SecondaryNumber of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Main Study + Observational Follow-up Combined

The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Main Study + Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Any event8157
Upper limb4117
Distal lower limb2416
Femur/hip1511
Spinal79
Pelvic03
Other74
SecondaryNumber of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Observational Follow-up

The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

Time frame:
From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Reported as:
Number · participants
Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Observational Follow-up
participantsCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Any event3521
Upper limb175
Distal lower limb98
Femur/hip64
Spinal23
Pelvic01
Other21
SecondaryNumber of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined00
SecondaryNumber of Participants With the Indicated Bone Fracture by Fracture Site: Main Study + Observational Follow-up Combined

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants With the Indicated Bone Fracture by Fracture Site: Main Study + Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Any event, overall; n=2220, 2227238151
Any event, male; n=1142, 11528260
Any event, female; n=1078, 107515691
Upper limb, any event, overall; n=2220, 222711670
Upper limb, any event, male; n=1142, 11523222
Upper limb, any event, female; n=1078, 10758448
Distal lower limb, any event, overall; n=2220, 2228840
Distal lower limb, any event, male; n=1142, 11523114
Distal lower limb, any event, female; n=1078, 10755726
Femur/hip, any event, overall; n=2220, 22271613
Femur/hip, any event, male; n=1142, 115241
Femur/hip, any event, female; n=1078, 10751212
Spinal, any event, overall; n=2220, 22271814
Spinal, any event, male; n=1142, 115279
Spinal, any event, female; n=1078, 1075115
Pelvic, any event, overall; n=2220, 222705
Pelvic, any event, male; n=1142, 115204
Pelvic, any event, female; n=1078, 107501
Unclassified, any event, overall; n=2220, 222710
Unclassified, any event, male; n=1142, 115210
Unclassified, any event, female; n=1078, 107500
Other, any event, overall; n=2220, 22273126
Other, any event, male; n=1142, 11521816
Other, any event, female; n=1078, 10751310
SecondaryNumber of Participants With the Indicated Bone Fracture by Fracture Site: Observational Follow-up

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

Time frame:
From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Reported as:
Number · participants
Number of Participants With the Indicated Bone Fracture by Fracture Site: Observational Follow-up
participantsCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Any event, overall; n=1280, 12506437
Any event, male; n=665, 6352511
Any event, female; n=615, 6153926
Upper limb, any event, overall; n=1280, 12503315
Upper limb, any event, male; n=665, 635103
Upper limb, any event, female; n=615, 6152312
Distal lower limb, any event, overall; n=1280,12501813
Distal lower limb, any event, male; n=665, 63594
Distal lower limb, any event, female; n=615, 61599
Femur/hip, any event, overall; n=1280, 125065
Femur/hip, any event, male; n=665, 63510
Femur/hip, any event, female; n=615, 61555
Spinal, any event, overall; n=1280, 125045
Spinal, any event, male; n=665, 63514
Spinal, any event, female; n=615, 61531
Pelvic, any event, overall; n=1280, 125001
Pelvic, any event, male; n=665, 63501
Pelvic, any event, female; n=615, 61500
Unclassified, any event, overall; n=1280, 125010
Unclassified, any event, male; n=665, 63510
Unclassified, any event, female; n=615, 61500
Other, any event, overall; n=1280, 125061
Other, any event, male; n=665, 63541
Other, any event, female; n=615, 61520
SecondaryNumber of Participants With Potentially High Morbidity Fractures: Main Study + Observational Follow-up Combined

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants With Potentially High Morbidity Fractures: Main Study + Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Any event, overall, n=2220, 22273131
Any event, male, n=1142, 11521013
Any event, female, n=1078, 10752118
Hip, overall, n=2220, 222797
Hip, male, n=1142, 115201
Hip, female, n=1078, 107596
Pelvis, overall, n=2220, 222705
Pelvis, male, n=1142, 115204
Pelvis, female, n=1078, 107501
Upper leg, overall, n=2220, 222776
Upper leg, male, n=1142, 115240
Upper leg, female, n=1078, 107536
Any vertebral event, overall, n=2220, 22271613
Any vertebral event, male, n=1142, 115268
Any vertebral event, female, n=1078, 1075105
Lumbar spine, overall, n=2220, 2227104
Lumbar spine, male, n=1142, 115253
Lumbar spine, female, n=1078, 107551
Thoracic spine, overall, n=2220, 222758
Thoracic spine, male, n=1142, 115214
Thoracic spine, female, n=1078, 107544
Cervical spine, overall, n=2220, 222711
Cervical spine, male, n=1142, 115201
Cervical spine, female, n=1078, 107510
SecondaryNumber of Participants With Potentially High Morbidity Fracture Events and Non-high Morbidity Fracture Events, in Participants With Prior Hand/Upper Arm/Foot Fractures (H/UA/FF): Main Study + Observational Follow-up Combined

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants With Potentially High Morbidity Fracture Events and Non-high Morbidity Fracture Events, in Participants With Prior Hand/Upper Arm/Foot Fractures (H/UA/FF): Main Study + Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Any H/UA/FF event, overall, n=2220, 22278646
Any H/UA/FF event, male, n=1142, 11522815
Any H/UA/FF event, female, n=1078, 10755831
High morbidity fractures, overall, n=2220, 222751
High morbidity fractures, male, n=1142, 115200
High morbidity fractures, female, n=1078, 107551
Non-high morbidity fractures, overall, n=2220, 222154
Non-high morbidity fractures, male, n=1142, 115223
Non-high morbidity fractures, female, n=1078, 1075131
SecondaryNumber of Participants With Bone Fracture Events of the Indicated Cause: Main Study + Observational Follow-up Combined

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · participants
Number of Participants With Bone Fracture Events of the Indicated Cause: Main Study + Observational Follow-up Combined
participantsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Any event238151
Non-traumatic event11355
Traumatic event11077
Pathologic14
Unknown2019
Data unavailable93
SecondaryNumber of Participants With Bone Fracture Events of the Indicated Cause: Observational Follow-up

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."

Time frame:
From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Reported as:
Number · participants
Number of Participants With Bone Fracture Events of the Indicated Cause: Observational Follow-up
participantsCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Any event6437
Non-traumatic event,3614
Traumatic event2417
Pathologic12
Unknown14
Data unavailable31
SecondaryNumber of Bone Fracture Events With the Indicated Outcome: Main Study + Observational Follow-up Combined

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."

Time frame:
From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)
Reported as:
Number · bone fracture events
Number of Bone Fracture Events With the Indicated Outcome: Main Study + Observational Follow-up Combined
bone fracture eventsCombined RSG: Main Study and Observational Follow-upCombined MET/SU: Main Study and Observational Follow-up
Number of bone fracture events299174
Unknown75
Normal healing with standard management250142
Complication1413
Additional therapeutic measures required169
Data unavailable125
SecondaryNumber of Bone Fracture Events With the Indicated Outcome: Observational Follow-up

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included "Unknown" as a category. Fracture events with missing outcome data were reported as "Data unavailable."

Time frame:
From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Reported as:
Number · bone fracture events
Number of Bone Fracture Events With the Indicated Outcome: Observational Follow-up
bone fracture eventsCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Number of bone fracture events7041
Unknown11
Normal healing with standard management5133
Complication74
Additional therapeutic measures required32
Data unavailable81
SecondaryNumber of Participants With the Indicated Serious Adverse Event: Observational Follow-up

The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.

Time frame:
From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)
Reported as:
Number · participants
Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up
participantsCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Any event9976
Ankle fracture63
Prostate cancer71
Lung neoplasm malignant44
Breast cancer26
Basal cell carcinoma43
Pancreatic carcinoma43
Colon cancer16
Humerus fracture51
Upper limb fracture51
Malignant melanoma32
Uterine cancer23
Gastric cancer40
Wrist fracture40
Hip fracture31
Radius fracture31
Forearm fracture22
Hepatic neoplasm malignant22
Rectal cancer22
Renal cancer22
Foot fracture13
Renal cell carcinoma30
Femur fracture21
Femoral neck fracture12
Lumbar vertebral fracture12
Metastases to bone12
Metastases to liver12
Bladder cancer20
Fall20
Metastases to central nervous system20
Rib fracture20
Squamous cell carcinoma20
Acute myocardial infarction11
Brain neoplasm11
Gastric neoplasm11
Metastases to lung11
Patella fracture11
Death02
Abdominal pain10
Acute myeloid leukaemia10
Acute respiratory failure10
Anaemia10
Benign salivary gland neoplasm10
Biliary colic10
Biliary neoplasm10
Bone neoplasm malignant10
Bronchial carcinoma10
Cardiac failure acute10
Chest pain10
Chronic lymphocytic leukaemia10
Colon neoplasm10
Contusion10
Drowning10
Dysplasia10
Endometrial cancer stage I10
Leukaemia10
Lower limb fracture10
Lung squamous cell carcinoma stage unspecified10
Lymphoma10
Malignant neoplasm of pleura10
Metastases to skin10
Metastases to testicle10
Metastatic renal cell carcinoma10
Oesophageal carcinoma10
Osteoarthritis10
Pancreatic necrosis10
Rectal cancer stage II10
Spinal fracture11
T-cell lymphoma11
Urinary tract infection11
Uterine leiomyosarcoma10
Biliary cancer metastatic01
Cervix carcinoma01
Chronic obstructive pulmonary disease01
Comminuted fracture01
Craniocerebral injury01
Gastrointestinal neoplasm01
Hepatic lesion01
Joint dislocation01
Laryngeal cancer01
Lip neoplasm malignant stage unspecified01
Lung neoplasm01
Metastases to lymph nodes01
Metastasis01
Musculoskeletal chest pain01
Myocardial infarction01
Non-Hodgkin's lymphoma01
Pubis fracture01
Pulmonary embolism01
Rectal cancer recurrent01
Rectal neoplasm01
Skin cancer01
Skin ulcer01
Small cell lung cancer stage unspecified01
Sternal fracture01
Subdural haemorrhage01
Sudden death01
Thoracic vertebral fracture01
Thyroid cancer01
Vulval cancer01

Adverse events

Collected over In the RECORD study (RS), SAEs were collected from BL through End of Study (up to 7.5 years); non-serious AEs were collected only for the randomized treatment period. SAEs were collected from the end of the RS through the end of OFU (up to 4.0 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSG in Addition to Background MET—424/1,117 (38%)1,117/1,117 (100%)
SU in Addition to Background MET—428/1,105 (38.7%)1,105/1,105 (100%)
RSG in Addition to Background SU—427/1,103 (38.7%)1,103/1,103 (100%)
MET in Addition to Background SU—431/1,122 (38.4%)1,122/1,122 (100%)
Combined RSG: Observational Follow-up—99/1,280 (7.7%)0/1,280 (0%)
Combined MET/SU: Observational Follow-up—76/1,250 (6.1%)0/1,250 (0%)
Most frequent serious events
Showing 10 of 838
Most frequent serious events
EventRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SUCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
Myocardial InfarctionCardiac disorders25/111722/110529/110323/11220/12801/1250
Cerebrovascular AccidentNervous system disorders18/111725/110521/110324/11220/12800/1250
Cardiac Failure CongestiveCardiac disorders25/111718/110523/110313/11220/12800/1250
Angina PectorisCardiac disorders23/111718/110523/110319/11220/12800/1250
Angina UnstableCardiac disorders16/111720/110521/110318/11220/12800/1250
PnuemoniaInfections and infestations21/111715/110511/110312/11220/12800/1250
Atrial FibrillationCardiac disorders20/111715/110513/110314/11220/12800/1250
Acute Myocardial InfarctionCardiac disorders12/11176/110511/110319/11221/12801/1250
Diabetes MellitusMetabolism and nutrition disorders4/11175/110510/110317/11220/12800/1250
Cardiac FailureCardiac disorders16/11171/110513/11038/11220/12800/1250
Most frequent other events
Showing 10 of 26
Most frequent other events
EventRSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SUCombined RSG: Observational Follow-upCombined MET/SU: Observational Follow-up
HypertensionVascular disorders345/1117372/1105302/1103319/11220/12800/1250
HyperlipidaemiaMetabolism and nutrition disorders236/1117144/1105193/1103120/11220/12800/1250
NasopharyngitisInfections and infestations216/1117202/1105121/1103122/11220/12800/1250
HypoglycaemiaMetabolism and nutrition disorders51/1117190/1105162/1103144/11220/12800/1250
HypercholesterolaemiaMetabolism and nutrition disorders121/111778/1105155/110364/11220/12800/1250
Back PainMusculoskeletal and connective tissue disorders153/1117143/110595/1103105/11220/12800/1250
Oedema peripheralGeneral disorders144/111747/1105133/110341/11220/12800/1250
BronchitisInfections and infestations139/1117128/1105136/1103122/11220/12800/1250
DiarrhoeaGastrointestinal disorders60/111781/110544/1103135/11220/12800/1250
InfluenzaInfections and infestations110/1117129/1105106/110388/11220/12800/1250

Baseline characteristics

Age, Continuous
Age, Continuous(years)RSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SUTotal
Mean57.0 ± 8.0257.2 ± 8.1459.8 ± 8.2659.7 ± 8.2358.4 ± 8.27
Sex: Female, Male
Sex: Female, Male(Participants)RSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SUTotal
Female5165215625542153
Male6015845415682294
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)RSG in Addition to Background METSU in Addition to Background METRSG in Addition to Background SUMET in Addition to Background SUTotal
White11051087109511124399
Black362314
Oriental425718
Aboriginal10001
African10001
Asian12104
Egyptian10001
Gipsy10001
Indian01001
Maori01001
Middle East Hible01001
Pacific Islander01001
Polynesian01001
Sri Lankan02002
Tahitian01001
08

Study locations

447 sites
  • GSK Investigational Site
    Miranda, New South Wales 2228, Australia
  • GSK Investigational Site
    Randwick, New South Wales 2031, Australia
  • GSK Investigational Site
    Wollongong, New South Wales 2500, Australia
  • GSK Investigational Site
    Carina Heights, Queensland 4152, Australia
  • GSK Investigational Site
    Kippa Ring, Queensland 4021, Australia
  • GSK Investigational Site
    Sherwood, Queensland 4075, Australia
  • GSK Investigational Site
    Keswick, South Australia 5035, Australia
  • GSK Investigational Site
    North Adelaide, South Australia 5006, Australia
  • GSK Investigational Site
    Port Lincoln, South Australia 5606, Australia
  • GSK Investigational Site
    Heidelberg, Victoria 3084, Australia
  • GSK Investigational Site
    Malvern, Victoria 3144, Australia
  • GSK Investigational Site
    Antwerpen, 2000, Belgium
  • GSK Investigational Site
    Arlon, 6700, Belgium
  • GSK Investigational Site
    Brussels, 1090, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Genk, 3600, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Kortrijk, 8500, Belgium
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Moerkerke, 8340, Belgium
  • GSK Investigational Site
    Oostham, 3945, Belgium
  • GSK Investigational Site
    Roeselare, 8800, Belgium
  • GSK Investigational Site
    Sint Gillis-Waas, 9170, Belgium
  • GSK Investigational Site
    Vilvoorde, 1800, Belgium
  • GSK Investigational Site
    Pleven, 5800, Bulgaria
  • GSK Investigational Site
    Plovdiv, 4002, Bulgaria
  • GSK Investigational Site
    Sofia, 1233, Bulgaria
  • GSK Investigational Site
    Sofia, 1301, Bulgaria
  • GSK Investigational Site
    Sofia, 1303, Bulgaria
  • GSK Investigational Site
    Sofia, 1431/1000, Bulgaria
  • GSK Investigational Site
    Sofia, 1606, Bulgaria
  • GSK Investigational Site
    Varna, 9010, Bulgaria
  • GSK Investigational Site
    Krapinske Toplice, 49217, Croatia
  • GSK Investigational Site
    Rijeka, 51000, Croatia
  • GSK Investigational Site
    Slavonski Brod, 35000, Croatia
  • GSK Investigational Site
    Varaždin, 42000, Croatia
  • GSK Investigational Site
    Zagreb, 10000, Croatia
  • GSK Investigational Site
    Brno, 625 00, Czech Republic
  • GSK Investigational Site
    Ceske Budejovice, 370 87, Czech Republic
  • GSK Investigational Site
    Holice V Cechach, 534 01, Czech Republic
  • GSK Investigational Site
    Hradec Kralove, 500 05, Czech Republic
  • GSK Investigational Site
    Jindrichuv Hradec, 377 38, Czech Republic
  • GSK Investigational Site
    Ostrava Poruba, 708 52, Czech Republic
  • GSK Investigational Site
    Pisek, 397 01, Czech Republic
  • GSK Investigational Site
    Praha 2, 128 42, Czech Republic
  • GSK Investigational Site
    Praha 4, 140 21, Czech Republic
  • GSK Investigational Site
    Rakovnik, 269 01, Czech Republic
  • GSK Investigational Site
    Tabor, 390 00, Czech Republic
  • GSK Investigational Site
    Trutnov, 541 21, Czech Republic
  • GSK Investigational Site
    Aalborg, DK-9100, Denmark
  • GSK Investigational Site
    Aarhus, Denmark
  • GSK Investigational Site
    Copenhagen, 2300, Denmark
  • GSK Investigational Site
    Glostrup, Denmark
  • GSK Investigational Site
    Hilleroed, 3400, Denmark
  • GSK Investigational Site
    Koge, 4600, Denmark
  • GSK Investigational Site
    Kolding, DK-6000, Denmark
  • GSK Investigational Site
    København NV, Denmark
  • GSK Investigational Site
    Naestved, 4700, Denmark
  • GSK Investigational Site
    Odense C, DK-5000, Denmark
  • GSK Investigational Site
    Silkeborg, 8600, Denmark
  • GSK Investigational Site
    Slagelse, 4200, Denmark
  • GSK Investigational Site
    Paide, 72714, Estonia
  • GSK Investigational Site
    Parnu, 80018, Estonia
  • GSK Investigational Site
    Rakvere, 44316, Estonia
  • GSK Investigational Site
    Saku, 75501, Estonia
  • GSK Investigational Site
    Tallinn, 10138, Estonia
  • GSK Investigational Site
    Tallinn, 1162, Estonia
  • GSK Investigational Site
    Tallinn, 11911, Estonia
  • GSK Investigational Site
    Tallinn, 13415, Estonia
  • GSK Investigational Site
    Tartu, Estonia
  • GSK Investigational Site
    Viljandi, 71024, Estonia
  • GSK Investigational Site
    Espoo, 02600, Finland
  • GSK Investigational Site
    Espoo, 02710, Finland
  • GSK Investigational Site
    Hanko, 10900, Finland
  • GSK Investigational Site
    Helsinki, 00150, Finland
  • GSK Investigational Site
    Helsinki, 00810, Finland
  • GSK Investigational Site
    Helsinki, 00930, Finland
  • GSK Investigational Site
    Hyvinkaa, 05800, Finland
  • GSK Investigational Site
    Jyväskylä, 40100, Finland
  • GSK Investigational Site
    Kerava, 04200, Finland
  • GSK Investigational Site
    Kuopio, 70210, Finland
  • GSK Investigational Site
    Lahti, 15850, Finland
  • GSK Investigational Site
    Lappeenranta, 53100, Finland
  • GSK Investigational Site
    Oulun kaupunki, 90015, Finland
  • GSK Investigational Site
    Riihimäki, 11130, Finland
  • GSK Investigational Site
    Rovaniemi, Finland
  • GSK Investigational Site
    Seinajoki, 60220, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20100, Finland
  • GSK Investigational Site
    Turku, 20700, Finland
  • GSK Investigational Site
    Bully Les Mines, Nord-Pas-de-Calais 62160, France
  • GSK Investigational Site
    Amilly, 28300, France
  • GSK Investigational Site
    Arras, 62000, France
  • GSK Investigational Site
    Aspach le Bas 68700, 68700, France
  • GSK Investigational Site
    Aubagne, 13400, France
  • GSK Investigational Site
    Auchy les Hesdin, 62770, France
  • GSK Investigational Site
    Azille, 11700, France
  • GSK Investigational Site
    Beaumont Le Roger, 21170, France
  • GSK Investigational Site
    Beaumont sur Leze, 31870, France
  • GSK Investigational Site
    Belfort, 90000, France

Showing the first 100 of 447 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P; RECORD Study Group. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med. 2007 Jun;24(6):626-34. doi: 10.1111/j.1464-5491.2007.02160.x. PubMed 17517066 ↗
  • Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia. 2005 Sep;48(9):1726-35. doi: 10.1007/s00125-005-1869-1. Epub 2005 Jul 16. PubMed 16025252 ↗
  • Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med. 2007 Jul 5;357(1):28-38. doi: 10.1056/NEJMoa073394. Epub 2007 Jun 5. PubMed 17551159 ↗
  • Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6. PubMed 19501900 ↗
  • Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD; RECORD Study Group. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol. 2008 Apr 24;7:10. doi: 10.1186/1475-2840-7-10. PubMed 18435852 ↗
  • Jones NP, Curtis PS, Home PD. Cancer and bone fractures in observational follow-up of the RECORD study. Acta Diabetol. 2015 Jun;52(3):539-46. doi: 10.1007/s00592-014-0691-y. Epub 2014 Dec 19. PubMed 25524432 ↗
  • MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, McMurray JJ. Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes Care. 2011 Jun;34(6):1394-6. doi: 10.2337/dc10-2398. Epub 2011 May 11. PubMed 21562320 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2001, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2006
First posted
Sep 22, 2006
Start
Apr 2001
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Nov 13, 2009
Last update
Mar 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00379769
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 22, 2006
Start date
Apr 2001
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Nov 13, 2009
Last update
Mar 23, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosiglitazone · Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea · Metformin

Start the discussion